Literature DB >> 7613832

Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?

F J Allen1, D J Van Velden, C F Heyns.   

Abstract

OBJECTIVE: To assess whether the presence of neuroendocrine (NE) cells is of value as an independent indicator of poor prognosis in patients with prostate carcinoma. PATIENTS AND METHODS: A series of 160 consecutive patients with prostate carcinoma was studied retrospectively. In 120 there was sufficient tissue for review and to perform immunoperoxidase stains for neuron specific enolase (NSE) and chromogranin A (CGA). All patients had a potential follow-up of at least 5 years.
RESULTS: Five-year survival was poorer for patients with a high tumour grade and stage at presentation compared to those with a lower grade and stage. NE cells were more common in higher grade and stage disease, but 5-year survival did not differ significantly between patients with NE cell positive and negative tumours.
CONCLUSION: NE cells are of no practical value as an independent prognostic indicator in patients with prostatic adenocarcinoma.

Entities:  

Mesh:

Year:  1995        PMID: 7613832     DOI: 10.1111/j.1464-410x.1995.tb07385.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  15 in total

1.  An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers.

Authors:  Joseph E Ippolito; Jian Xu; Sanjay Jain; Krista Moulder; Steven Mennerick; Jan R Crowley; R Reid Townsend; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-05       Impact factor: 11.205

2.  [Relevance of the neuroendocrine differentiation in prostatic carcinoma].

Authors:  C G Sauer; L Trojan; R Grobholz
Journal:  Pathologe       Date:  2005-11       Impact factor: 1.011

3.  Prostate cancer and neuroendocrine differentiation.

Authors:  M O Tan; U Karaoğlan; B Celik; O Ataoğlu; H Biri; I Bozkirli
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

4.  Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer.

Authors:  S S Jeetle; G Fisher; Z H Yang; E Stankiewicz; H Møller; C S Cooper; J Cuzick; D M Berney
Journal:  Virchows Arch       Date:  2012-07-06       Impact factor: 4.064

5.  A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

Authors:  Lawrence D True; Kent Buhler; Janna Quinn; Emily Williams; Peter S Nelson; Nigel Clegg; Jill A Macoska; Thomas Norwood; Alvin Liu; William Ellis; Paul Lange; Robert Vessella
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

6.  Gamma-enolase predicts lung damage in severe acute pancreatitis-induced acute lung injury.

Authors:  Lawrence Owusu; Caiming Xu; Hailong Chen; Geliang Liu; Guixin Zhang; Jinwen Zhang; Zhankai Tang; Zhongwei Sun; Xin Yi
Journal:  J Mol Histol       Date:  2018-05-04       Impact factor: 2.611

7.  Orexin expression in different prostate histopathologic examinations: Can it be a marker for prostate cancer? A preliminary result.

Authors:  Murad Mehmet Başar; Ünsal Han; Murat Çakan; Serhan Alpcan; Halil Başar
Journal:  Turk J Urol       Date:  2013-06

Review 8.  Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.

Authors:  David S Priemer; Rodolfo Montironi; Lisha Wang; Sean R Williamson; Antonio Lopez-Beltran; Liang Cheng
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

9.  Neuroendocrine differentiation in gastric adenocarcinomas; correlation with tumor stage and expression of VEGF and p53.

Authors:  Funda Eren; Ciğdem Celikel; Bahadir Güllüoğlu
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

Review 10.  Small cell carcinoma of the prostate.

Authors:  Rosa Nadal; Michael Schweizer; Oleksandr N Kryvenko; Jonathan I Epstein; Mario A Eisenberger
Journal:  Nat Rev Urol       Date:  2014-02-18       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.